All of the above‐mentioned results indicated that drug sensitivity to DDP could be restored by miR‐335‐5p through downregulating the expression of BCL2L2 in DDP‐resistant ovarian cancer cells. This evidence concerns the gene BCL2L2 and ovarian cancer.